Search - tctmd.com

Displaying 1 - 20 of 30

Sort: Relevancy | Date

Presentation TCT 2025

TCT 488: Sex-Based Differences in Cardiovascular Outcomes With Achieved LDL-C <55 mg/dL: A Comparative Cohort Analysis

Presenter: Mehmet Cilingiroglu

October 28, 2025

Presentation TCT 2025

Optimizing PCI Outcomes After ACS: Lipid Modification Therapies - LDL, Lp(a) and Beyond

Presenter: Marc P. Bonaca

October 27, 2025

Presentation TCT 2025

TCT 481: Strike Early, Strike Strong—But Retest Early as Well: Two-Week LDL-C Assessment Accurately Identifies Non-Responders to Triple Oral Lipid-Lowering Therapy in ACS Patients Undergoing PCI

Presenter: Kunal Mahajan

October 27, 2025

Presentation TCT 2025

TCT 470: Comparative Outcomes of Serum LDL Levels <55 mg/dL Versus 55–100 mg/dL for Primary Prevention of Undiagnosed Coronary Artery Disease: A Retrospective Cohort Study

Presenter: Mehmet Cilingiroglu

October 27, 2025

Presentation TCT 2025

TCT 475: Impact of Elevated Lipoprotein(a) on LDL Cholesterol Target Attainment Following PCI for Acute Coronary Syndrome Despite Intensive Triple Oral Lipid-Lowering Therapy: A Retrospective Cohort Study

Presenter: Kunal Mahajan

October 27, 2025

Presentation TCT 2025

ACS Pharma Trials On The Horizon: LDL Lowering Therapies

Presenter: Angelo Oliva

October 26, 2025

Presentation TCT India 2025

Beat the Clock: Early & Sustained LDL-C Control for Lifelong Cardiac Protection

Presenter: Nakul Sinha, Rajendra Kumar Jain, & Viveka Kumar

July 26, 2025

Presentation TCT 2024

What Happens Next? Beyond Statins for Optimizing LDL-C Management After Coronary and Peripheral Intervention

Presenter: David Kwon

October 29, 2024

Presentation TCT 2024

LDL Lowering in ACS- Go Big, Go Early, Then Go Home

Presenter: Marc Bonaca

October 29, 2024

Presentation TCT 2024

Changes in Plaque Volume and Plaque Composition After 12 Weeks of Extensive LDL-C Reduction With PCSK9 Inhibitors in ACS Patients With Multivessel Disease

Presenter: Jonathan Los

October 27, 2024

Presentation TCT 2023

Beyond LDL

Presenter: Pieter Smits

October 26, 2023

Presentation TCT 2023

Applying New LDL-C Lowering Agents: Update on PCSK9mab, Inclisaran, and Bempedoic Acid

Presenter: Karol Watson

October 26, 2023

Presentation TCT 2023

TCT 555: NIRS-Detected Lipid-Rich Plaques are Highly Responsive to Novel Escalated LDL-C Reduction Therapy

Presenter: Karlis Trusinskis

October 25, 2023

Presentation Complex Coronary Cases 2023

LDL-c reduction: how low can you go?

Presenter: Gabriel Steg

June 15, 2023

Presentation TCT 2020

TCT 362: Natural Vascular Scaffolding Therapy Shows Favorable Biocompatibility and Protection of Elastin Content in Comparison to Balloon Angioplasty and Stent in Peripheral Arteries of LDLR-Knockout Hypercholesterolemic Swine

Presenter: Greg Kaluza

October 14, 2020

Presentation ACC 2020

Alirocumab Efficacy And Safety In Adults With Homozygous Familial Hypercholesterolemia (ODYSSEY HoFH)

Presenter: Dirk J. Blom

March 30, 2020

Presentation JIM 2020

Optimal LDL levels in patients with ACS undergoing PCI

Presenter: Giuseppe Musumeci

February 13, 2020

Presentation JIM 2020

Ultra LOW LDL is the target for high risk patients

Presenter: Francesco Prati

February 13, 2020

Presentation JIM 2020

Optimal LDL Levels In Patients With ACS Undergoing PCI Clinical Case: PCI In ACS Patients With Multivessel Disease

Presenter: Ferdinando Varbella

February 13, 2020

Presentation TCT 2019

Optimizing LDL-C Management in Patients Undergoing Revascularization: More Than Just the Metal

Presenter: Aloke Finn

September 28, 2019

Advertisement

TCT 488: Sex-Based Differences in Cardiovascular Outcomes With Achieved LDL-C <55 mg/dL: A Comparative Cohort Analysis

Optimizing PCI Outcomes After ACS: Lipid Modification Therapies - LDL, Lp(a) and Beyond

TCT 481: Strike Early, Strike Strong—But Retest Early as Well: Two-Week LDL-C Assessment Accurately Identifies Non-Responders to Triple Oral Lipid-Lowering Therapy in ACS Patients Undergoing PCI

TCT 470: Comparative Outcomes of Serum LDL Levels <55 mg/dL Versus 55–100 mg/dL for Primary Prevention of Undiagnosed Coronary Artery Disease: A Retrospective Cohort Study

TCT 475: Impact of Elevated Lipoprotein(a) on LDL Cholesterol Target Attainment Following PCI for Acute Coronary Syndrome Despite Intensive Triple Oral Lipid-Lowering Therapy: A Retrospective Cohort Study

ACS Pharma Trials On The Horizon: LDL Lowering Therapies

Beat the Clock: Early & Sustained LDL-C Control for Lifelong Cardiac Protection

What Happens Next? Beyond Statins for Optimizing LDL-C Management After Coronary and Peripheral Intervention

LDL Lowering in ACS- Go Big, Go Early, Then Go Home

Changes in Plaque Volume and Plaque Composition After 12 Weeks of Extensive LDL-C Reduction With PCSK9 Inhibitors in ACS Patients With Multivessel Disease

Beyond LDL

Applying New LDL-C Lowering Agents: Update on PCSK9mab, Inclisaran, and Bempedoic Acid

TCT 555: NIRS-Detected Lipid-Rich Plaques are Highly Responsive to Novel Escalated LDL-C Reduction Therapy

LDL-c reduction: how low can you go?

TCT 362: Natural Vascular Scaffolding Therapy Shows Favorable Biocompatibility and Protection of Elastin Content in Comparison to Balloon Angioplasty and Stent in Peripheral Arteries of LDLR-Knockout Hypercholesterolemic Swine

Alirocumab Efficacy And Safety In Adults With Homozygous Familial Hypercholesterolemia (ODYSSEY HoFH)

Optimal LDL levels in patients with ACS undergoing PCI

Ultra LOW LDL is the target for high risk patients

Optimal LDL Levels In Patients With ACS Undergoing PCI Clinical Case: PCI In ACS Patients With Multivessel Disease

Optimizing LDL-C Management in Patients Undergoing Revascularization: More Than Just the Metal

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content